AlphaCrest Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,434
Closed -$464K 642
2022
Q3
$464K Sell
1,434
-6,799
-83% -$2.15M 0.03% 1010
2022
Q2
$2.67M Buy
8,233
+2,051
+33% +$616K 0.13% 196
2022
Q1
$1.77M Sell
6,182
-2,708
-30% -$697K 0.1% 286
2021
Q4
$2.46M Sell
8,890
-16,650
-65% -$4.22M 0.09% 325
2021
Q3
$5.9M Buy
25,540
+9,786
+62% +$2.42M 0.31% 34
2021
Q2
$3.62M Sell
15,754
-42,764
-73% -$8.59M 0.16% 177
2021
Q1
$10.9M Buy
58,518
+48,061
+460% +$9.4M 0.61% 12
2020
Q4
$1.77M Sell
10,457
-12,544
-55% -$1.87M 0.15% 168
2020
Q3
$3.4M Buy
23,001
+12,836
+126% +$1.99M 0.37% 26
2020
Q2
$1.67M Sell
10,165
-16,380
-62% -$2.51M 0.28% 60
2020
Q1
$3.68M Buy
26,545
+24,345
+1,107% +$3.34M 0.45% 8
2019
Q4
$289K Sell
2,200
-13,475
-86% -$1.56M 0.02% 1083
2019
Q3
$1.75M Sell
15,675
-55,353
-78% -$6.16M 0.11% 295
2019
Q2
$7.87M Buy
71,028
+68,609
+2,836% +$8.08M 0.68% 2
2019
Q1
$314K Sell
2,419
-1,781
-42% -$217K 0.05% 642
2018
Q4
$486K Buy
+4,200
New +$469K 0.14% 254

Other funds holding LLY

AlphaCrest Capital Management's LLY Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Eli Lilly (LLY) in Q4 2022, closing a stake of 1,434 shares — an estimated $464K sold.

AlphaCrest Capital Management first reported a position in LLY in Q4 2018 and held it in 16 quarters. The position peaked at $10.9M in Q1 2021. 2,671 funds tracked by Wall St. Rank hold LLY as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Eli Lilly position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 1,434 Eli Lilly shares in Q4 2022, an estimated $464K.
  • AlphaCrest Capital Management first reported a position in Eli Lilly in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's Eli Lilly position peaked at $10.9M in Q1 2021.
  • 2,671 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.